Drug General Information (ID: DDI1XCWHJ2)
Drug Name			Medroxyprogesterone acetate		Drug Info		Asparaginase Erwinia chrysanthemi		Drug Info
Drug Type		Small molecule				Protein/peptide
Therapeutic Class		Contraceptives/Hormones/Antineoplastics				Antineoplastics

Mechanism of Medroxyprogesterone acetate-Asparaginase Erwinia chrysanthemi Interaction (Severity Level: Moderate)
Decreased metabolism due to hepatotoxicity Click to Show/Hide Mechanism Graph
Drug Name		Medroxyprogesterone acetate				Asparaginase Erwinia chrysanthemi
Mechanism		Metabolized by the liver				Hepatotoxicity
Key Mechanism Factor 1
		Factor Name		Hepatotoxicity
		Factor Description		Drug-induced hepatotoxicity is an acute or chronic liver injury secondary to drugs. The metabolism of drugs is reduced when the liver is damaged and fewer enzymes are synthesized by the liver.
Mechanism Description		Decreased metabolism of Medroxyprogesterone acetate caused by Asparaginase Erwinia chrysanthemi mediated hepatotoxicity

Recommended Action
Management		The use of oral contraceptives during asparaginase treatment is not recommended. Other non-oral contraceptive methods should be used in women of childbearing potential. According to the manufacturer, females of reproductive potential should be advised to use effective contraception during asparaginase treatment and for at least 3 to 6 months after the last dose.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
3	Product Information. Asparlas (calaspargase pegol). Servier, Boston, MA.